淋巴瘤
生发中心
表型
T细胞
癌症研究
细胞毒性T细胞
免疫系统
外周血单个核细胞
免疫疗法
弥漫性大B细胞淋巴瘤
医学
免疫学
B细胞
生物
抗体
体外
生物化学
基因
作者
Emilie Réboursière,Anne-Claire Gac,Anthony Garnier,Véronique Salaün,Oumédaly Reman,Anne-Dominique Pham,Quentin Cabrera,Kathy Khoy,Jean-Pierre Vilque,Christophe Fruchart,Sylvain Chantepie,Hyacinthe Johnson‐Ansah,Margaret Macro,Stéphane Chèze,Khaled Benabed,Jean-Baptiste Méar,Xavier Troussard,Gandhi Damaj,Brigitte Le Mauff,Olivier Toutirais
标识
DOI:10.1080/10428194.2017.1321751
摘要
Gamma-delta (γδ) T cells contribute to the innate immune response against cancer. In samples of 20 patients upon DLBCL diagnosis, we found that Vδ1+ T cells were the major γδ T cell subset in tumors and PBMCs of patients, while Vδ2 T cells were preponderant in PBMCs of healthy subjects. Interestingly, the germinal center (GC) subtype was associated with an increase in Vδ1+ T cells in tumors, whereas the non-GC subtype was associated with a lower frequency of γδ T cells. While circulating Vδ1+ T cells of patients or HSs mostly exhibited a naïve phenotype, the majority of tumor Vδ1+ T cells showed a central memory phenotype. Resident or circulating γδ T cells from patients were not functionally impaired since they produced high levels of IFN-γ. Collectively, our findings are in favor of γδ T cell activation in tumors and open new perspectives for their modulation in DLBCL immunotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI